Inivata Announces Strategic Partnership with Levine Cancer Institute and Formation of the Inivata Knowledge Accumulation Network
Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid biopsy platform to transform patient care today announces a strategic partnership with Carolinas HealthCare System’s Levine Cancer Institute and the subsequent formation of the Inivata Knowledge Accumulation Network (IKAN).
Levine Cancer Institute becomes the founding member of IKAN, which will be a global network of world-leading cancer centers working in partnership with Inivata to assess the potential of liquid biopsy to transform cancer care and improve patient outcomes.
Edward Kim, Solid Tumor Oncology and Investigational Therapeutics & Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, said:
“Inivata’s InVision TM liquid biopsy platform is innovative, highly sensitive and has great potential in clinical practice. I am delighted to be working with the first-class team at Inivata in the official formation of IKAN. The network will serve to facilitate our common goal of improving treatment decisions and outcomes for patients. We already have a number of projects underway, including a recent grant from the V Foundation, to explore the various applications of ctDNA in revolutionizing patient management.”
Clive Morris, Chief Medical Officer of Inivata, said:
“We are excited to be partnering with the world-leading Levine Cancer Institute to form the Inivata Knowledge Accumulation Network. The sharing of knowledge between world-leaders is crucial for continued advancement of the field, and we anticipate IKAN will provide an efficient platform for innovative conversations and collaborations. The opportunity to continue our work with leading cancer centers on a range of clinical projects across different cancer types, will enable the swift development and validation of our InVision platform.”
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.